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This issue of Applied Health Economics and
HealthPolicy includes a detailed description of the
National Institute for Health and Clinical Ex-
cellence (NICE) guidance, and of its development,
on the adoption into practice of the ‘PleurX
peritoneal catheter drainage system for vacuum-
assisted drainage of treatment-resistant, recurrent
malignant ascites’.[1] This is the ninth piece of
Medical Technologies Guidance on a diverse
range of devices and diagnostics (table I).
The aim of this Commentary is to provide some
background to the NICE Medical Technologies
Evaluation Programme (MTEP), and to why the
assessment reports – which will be summarized in
this journal – are vital to its methodology.
1. Background and Principles of
Operation
In 2009, NICE was given responsibility for
establishing a system to identify and, subject to
evaluation, encourage adoption of new or novel
medical devices and diagnostic technologies with
potential to improve the experience and out-
comes of patients and/or to drive efficiencies in
the use of health-service resources.
The NICE Medical Technologies Programme,
and the specialist Diagnostic Assessment Pro-
gramme, were constructed through a wide-ranging
series of discussions with many interested parties –
industry, clinicians, commissioners, health-service
Table I. Published Medical Technologies Guidance (MTG)
MTG Title Date issued
MTG1 SeQuent Please balloon catheter for in-stent coronary restenosis Dec 2010
MTG2 MoorLDI2 Burns Imager a laser Doppler blood flow imager for the assessment of burn wounds Mar 2011
MTG3 CardioQ-ODM (oesophageal Doppler monitor) Mar 2011
MTG4 BRAHMS copeptin assay to rule out myocardial infarction in patients with acute chest pain Jun 2011
MTG5 MIST Therapy system for the promotion of wound healing in chronic and acute wounds Jul 2011
MTG6 Ambulight photodynamic therapy for the treatment of non-melanoma skin cancer Jul 2011
MTG7 Inditherm patient warming mattress for the prevention of inadvertent hypothermia Aug 2011
MTG8 The VeriQ system for assessing graft flow during coronary artery bypass graft surgery Nov 2011
MTG9 PleurX peritoneal catheter drainage system for vacuum assisted drainage of treatment-resistant recurrent
malignant ascites
Mar 2012
MTG10 Pipeline embolisation device for the treatment of complex intracranial aneurysms May 2012
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managers, academics, scientists and patients. The
result is a programme where the following princi-
ples of operation reflect the distinct characteristics
of innovative medical technologies.
 All forms of evidence (published and unpub-
lished and with no design or quality threshold)
are considered, reflecting the often sparse evi-
dence base for medical technologies.
 The evaluation timeline is as short as possible
to reflect the often rapid pace of development
of technologies.
 The initial assessment of a technology is based
on the claims made for a single product: to
simulate the decision making in health systems
and ensure that guidance is as relevant as
possible. During evaluation, the guidance is
based on a sponsor’s submission, including cost
modelling (on a template specified by NICE).
Clear and explicit value propositions about all
aspects of introducing technologies in place of
‘current management’ are central to evaluations.
 System benefits are given equal prominence to
patient benefits and sustainability benefits are
identified and actively considered.
 Technologies are notified to NICE by innova-
tors (usually a commercial sponsor, i.e. man-
ufacturer or distributor) so that the full range
of medical technology products is considered.
 Products which are novel but not new can
be notified and may be evaluated if there is
evidence that they have plausible claimed bene-
fits and are not being routinely adopted.
 Medical Technologies Guidances specifically
examine products which are plausibly resource-
releasing. The economic method used is cost-
consequences analysis where the inputs and
outcomes are costs rather than any patient-based
outcome such as quality-adjusted life-years.
The programme has a dual function: first, to
select the most promising technologies from those
notified and route them to the most appropriate
NICE programme. Second, to carry out evalua-
tions which are published as Medical Technolo-
gies Guidance. Thus, topics such as the PleurX
peritoneal drainage system are ‘self-referred’. The
selection process is designed to ensure that only
new or novel products with plausible promise are
routed for evaluation. The option to route to the
most appropriate NICE programme ensures
flexibility in enabling a wide range of products,
with different value propositions, to be handled.
A particularly important routing option is to the
NICE Diagnostics Assessment Programme which
was launched in 2010. This is a specialist pro-
gramme designed to evaluate complex decision
problems relating to diagnostic technologies and
whose economic methods include cost-effectiveness
analysis.
In summary, the purpose of the programmes is
to encourage early uptake of technologies which
offer advantages for patients and for the UK
National Health Service (NHS), compared with
current methods of management. The NICE
MTEP has been identified as the central source of
guidance on medical technologies in the report:
Innovation, Health and Wealth by the NHS Chief
Executive.[2]
2. Process and Methods
The MTEP draws on the core principles of all
NICE guidance. It is based on the best evidence
available; uses and values input from experts,
patients and carers; involves decision making by
independent advisory committees, genuine con-
sultation and regular review; and has open and
transparent processes. The Programme’s Process
and Methods Guides were published in April 2011
following public consultation and are available on
the NICE web site (www.nice.org.uk/mt).
For products notified and selected for develop-
ment of Medical Technologies Guidance, NICE
first develops and publishes a scope. The next im-
portant step is production of a submission by the
sponsor. This includes the clinical evidence and
cost modelling which specifically supports the
claimed benefits in the sponsor’s case for adoption.
The submission is critically reviewed by an ex-
ternal academic group with expertise and experi-
ence in health technology assessment of medical
technologies. The submission and this critique
are the key evidence used by the independent
Medical Technologies Advisory Committee in its
decision making. A particular blend of skills and
experience are required for health technology
assessment of medical devices and diagnostics.
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Based on an innovative service specification, and
after a public procurement process, NICE now
contracts with four external assessment centres
(EACs), including the Cedar group which has
published the article in this edition of the journal,
to provide this expertise.
The key output from the EAC during the de-
velopment of Medical Technologies Guidance is
the assessment report. This report draws together
the EAC’s critique of the sponsor’s submission,
including:
 the literature search strategy;
 the quality and relevance of the clinical evidence;
 the choice of comparator;
 the quality of the economic model, including
the assumptions made, and any scenario or
sensitivity analysis carried out. The EAC may
carry out further analyses where the original
submission is inadequate.
During the preparation of the assessment re-
port, the EAC will consult with the sponsor and
with clinical and patient experts, particularly
when there are uncertainties.
3. Resolving Uncertainties
When all of the analytical work is complete,
and the Advisory Committee is considering the
technology, uncertainties frequently arise on which
the EAC is able to provide expertise and insights
from their work. For example, there may turn out
to be an unexpected paucity of good evidence;
certain assumptions used for cost modelling which
are not plausible; expert opinions which call into
question the likelihood that the technology will fit
into care pathways or produce the clinical benefits
which are claimed. In addition, it is unusual for
the published evidence to provide clear answers
about all the clinical utility issues. These un-
certainties mean that debate is often difficult
and complex, but the Committee needs to decide
whether, on balance, the evidence is sufficient to
support the case for adoption of the technology
by the NHS (perhaps for defined indications).
Sometimes a technology is judged to have real
promise but aspects of the available evidence are
insufficient. In these circumstances, the committee
can make recommendations for further research.
In such cases, NICE now has a mechanism for
facilitating such research, through the EACs.
In conclusion, the NICE MTEP is a novel
health technology assessment initiative which in-
corporates world-leading clinical, scientific and
academic support in its processes and methods.
Its Medical Technologies Guidance offers a
valuable aid for NHS decision makers. The guid-
ance states whether the available evidence supports
the case for adopting a technology as an alternative
to current (clearly described) management. It de-
scribes the advantages of doing so for patients
and for the service; and outlines changes to care
pathways that introducing the technology would
require. It presents the cost consequences, calcu-
lated over an appropriate length of time. This kind
of recommendation and explicit description of
likely outcomes ought to furnish commissioners
and providers with all the information they need
to make decisions about developing their services
through the purchase of new technologies. It
should assist clinicians who want to introduce tech-
nologies and may influence those who are un-
certain; and it may provide a useful tool for patients
who are keen to gain access to new technologies
which will help them.
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